Conexeu Sciences Signals a Major Breakthrough in 'Personalized Human Tissue Creation'
Reno, Nevada--(Newsfile Corp. - November 20, 2025) - Conexeu Sciences Inc. ("Conexeu" or the "Company"), a biotechnology innovator redefining regenerative medicine through a next-generation collagen-based platform, is pleased to announce that it has achieved a defining milestone in regenerative medicine with the first ever 3D-printed structures made entirely from its patented, functional extracellular matrix (ECM). Using its patented CXU™ platform, the Company has printed bovine-derived...
2025-11-20 9:00 AM EST
Conexeu Sciences Inc. Expands Board of Directors with the Appointments of Dr. Aaron Farberg and Dr. Sebastian Purcell
Reno, Nevada--(Newsfile Corp. - November 5, 2025) - Conexeu Sciences Inc. ("Conexeu" or the "Company"), a biotechnology innovator redefining regenerative medicine through a next-generation collagen-based platform, today announced the appointments of Aaron Farberg, M.D. and Sebastian Purcell, Ph.D. to its Board of Directors. The additions bring together leading expertise from the worlds of medicine, science, and ethics-driven innovation as Conexeu advances its mission to pioneer collagen-based...
2025-11-05 7:00 AM EST
Conexeu Sciences Appoints Miles Harrison as President & Chief Executive Officer, to Shape the Future of True Tissue Regeneration
Reno, Nevada--(Newsfile Corp. - November 3, 2025) - Conexeu Sciences Inc. ("Conexeu" or the "Company"), a pre-commercial biotechnology company redefining regenerative medicine through next-generation collagen science, announces the appointment of Miles D. Harrison as President & Chief Executive Officer of the Company. He has also been appointed to the Company's Board of Directors.At Conexeu, Miles will lead the Company's next phase of growth, advancing its first-in-class collagen platform for...
2025-11-03 7:00 AM EST
Conexeu Sciences Closes Maximum $5M Reg CF Financing
Reno, Nevada--(Newsfile Corp. - October 16, 2025) - Conexeu Sciences Inc. (the "Company" or "Conexeu") a biotechnology company revolutionizing tissue regeneration, is pleased to announce the completion of its $5 million Regulation Crowdfunding (Reg CF) financing. Conexeu secured commitments in excess of $5 million in less than two weeks from the date of launching the financing through the Equifund platform. Conexeu Chief Executive Officer, Jeff Sharpe, stated, "This milestone highlights the...
2025-10-16 9:01 AM EDT